IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32043-3.html
   My bibliography  Save this article

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis

Author

Listed:
  • Manse Kim

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

  • Claire E. Johnson

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

  • Alan A. Schmalstig

    (University of North Carolina at Chapel Hill)

  • Ayano Annis

    (University of North Carolina at Chapel Hill)

  • Sarah E. Wessel

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

  • Brian Horn

    (University of North Carolina at Chapel Hill)

  • Amanda Schauer

    (University of North Carolina at Chapel Hill)

  • Agata A. Exner

    (Case Western Reserve University)

  • Jason E. Stout

    (Duke University)

  • Angela Wahl

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

  • Miriam Braunstein

    (University of North Carolina at Chapel Hill)

  • J. Victor Garcia

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

  • Martina Kovarova

    (University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill)

Abstract

Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (Mtb) and is a major cause of morbidity and mortality. Successful treatment requires strict adherence to drug regimens for prolonged periods of time. Long-acting (LA) delivery systems have the potential to improve adherence. Here, we show the development of LA injectable drug formulations of the anti-TB drug rifabutin made of biodegradable polymers and biocompatible solvents that solidifies after subcutaneous injection. Addition of amphiphilic compounds increases drug solubility, allowing to significantly increase formulation drug load. Solidified implants have organized microstructures that change with formulation composition. Higher drug load results in smaller pore size that alters implant erosion and allows sustained drug release. The translational relevance of these observations in BALB/c mice is demonstrated by (1) delivering high plasma drug concentrations for 16 weeks, (2) preventing acquisition of Mtb infection, and (3) clearing acute Mtb infection from the lung and other tissues.

Suggested Citation

  • Manse Kim & Claire E. Johnson & Alan A. Schmalstig & Ayano Annis & Sarah E. Wessel & Brian Horn & Amanda Schauer & Agata A. Exner & Jason E. Stout & Angela Wahl & Miriam Braunstein & J. Victor Garcia , 2022. "A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32043-3
    DOI: 10.1038/s41467-022-32043-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32043-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32043-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. S. Rahima Benhabbour & Martina Kovarova & Clinton Jones & Daijha J. Copeland & Roopali Shrivastava & Michael D. Swanson & Craig Sykes & Phong T. Ho & Mackenzie L. Cottrell & Anush Sridharan & Samantha, 2019. "Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery," Nature Communications, Nature, vol. 10(1), pages 1-12, December.
    2. Martina Kovarova & S. Rahima Benhabbour & Ivana Massud & Rae Ann Spagnuolo & Brianna Skinner & Caroline E. Baker & Craig Sykes & Katie R. Mollan & Angela D. M. Kashuba & J. Gerardo García-Lerma & Russ, 2018. "Ultra-long-acting removable drug delivery system for HIV treatment and prevention," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    3. Abriham Zegeye & Getnet Dessie & Fasil Wagnew & Alemu Gebrie & Sheikh Mohammed Shariful Islam & Bekele Tesfaye & Dessalegn Kiross, 2019. "Prevalence and determinants of anti-tuberculosis treatment non-adherence in Ethiopia: A systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-15, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Suyash Deodhar & Brady Sillman & Aditya N. Bade & Sean N. Avedissian & Anthony T. Podany & JoEllyn M. McMillan & Nagsen Gautam & Brandon Hanson & Bhagya L. Dyavar Shetty & Adam Szlachetka & Morgan Joh, 2022. "Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    2. Isabella C. Young & Ivana Massud & Mackenzie L. Cottrell & Roopali Shrivastava & Panita Maturavongsadit & Alka Prasher & Andres Wong-Sam & Chuong Dinh & Tiancheng Edwards & Victoria Mrotz & James Mitc, 2023. "Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    3. Kirubel Manyazewal Mussie & Solomon Abebe Yimer & Tsegahun Manyazewal & Christoph Gradmann, 2019. "Exploring local realities: Perceptions and experiences of healthcare workers on the management and control of drug-resistant tuberculosis in Addis Ababa, Ethiopia," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-16, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32043-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.